caa a22 4500 445298812 CHVBK 20180317142550.0 cr unu---uuuuu 170323e20100601xx s 000 0 eng 10.1007/s11864-010-0115-3 doi (NATIONALLICENCE)springer-10.1007/s11864-010-0115-3 Circulating Tumor Cells in Colorectal Cancer: Past, Present, and Future Challenges [Elektronische Daten] [Benjamin Negin, Steven Cohen] Opinion statement: Recent advances in immunomagnetic separation and flow cytometry have made the detection and characterization of circulating tumor cells (CTC) a reality. This technology has already demonstrated prognostic significance in breast and prostate cancer. In the current review, we will review the historical and current data regarding the enumeration and identification of CTC in colorectal cancer. With immunomagnetic separation techniques, CTC can reliably and reproducibly be identified within 1 to 2 cells in a 7.5mL sample of peripheral blood. Prospective studies have demonstrated a significant adverse impact on survival with the presence of ≥3 CTC per 7.5mL blood. Approximately one quarter of patients with metastatic disease will be categorized in this poor prognosis group. In addition, change in number of cells on treatment has prognostic significance. While CTC enumerated through immunomagnetic separation are a clear prognostic factor for patients with mCRC, the future challenge is to study whether treatment decision-making should be impacted by their level. Low cell yield in mCRC is a potential hinderance to answering these important clinical questions at present. CTC can also be isolated and studied with flow cytometry, FISH, and RT-PCR, allowing real-time assessment of tumor biology. Future advances in this field will improve both the detection and manipulation of these cells. Improvements in detection and characterization of CTC will hopefully lead to refinement of the surgical and chemotherapeutic treatment of colorectal cancer. Springer Science+Business Media, LLC, 2010 Negin Benjamin Department of Medical Oncology, Fox Chase Cancer Center, 333 Cottman Avenue, 19111, Philadelphia, PA, USA aut Cohen Steven Department of Medical Oncology, Fox Chase Cancer Center, 333 Cottman Avenue, 19111, Philadelphia, PA, USA aut Current Treatment Options in Oncology Springer US; http://www.springer-ny.com 11/1-2(2010-06-01), 1-13 1527-2729 11:1-2<1 2010 11 11864 https://doi.org/10.1007/s11864-010-0115-3 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/s11864-010-0115-3 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Negin Benjamin Department of Medical Oncology, Fox Chase Cancer Center, 333 Cottman Avenue, 19111, Philadelphia, PA, USA aut NATIONALLICENCE 700 1- Cohen Steven Department of Medical Oncology, Fox Chase Cancer Center, 333 Cottman Avenue, 19111, Philadelphia, PA, USA aut NATIONALLICENCE 773 0- Current Treatment Options in Oncology Springer US; http://www.springer-ny.com 11/1-2(2010-06-01), 1-13 1527-2729 11:1-2<1 2010 11 11864 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer